Synonym
Ro 43-5054; Ro-43-5054; Ro43-5054; Ro 435054; Ro-435054; Ro435054;
IUPAC/Chemical Name
(S)-3-(3-(4-carbamimidoylbenzamido)propanamido)-4-(((S)-1-carboxy-2-phenylethyl)amino)-4-oxobutanoic acid
InChi Key
XPXOBWWMCFKOKQ-ROUUACIJSA-N
InChi Code
InChI=1S/C24H27N5O7/c25-21(26)15-6-8-16(9-7-15)22(33)27-11-10-19(30)28-17(13-20(31)32)23(34)29-18(24(35)36)12-14-4-2-1-3-5-14/h1-9,17-18H,10-13H2,(H3,25,26)(H,27,33)(H,28,30)(H,29,34)(H,31,32)(H,35,36)/t17-,18-/m0/s1
SMILES Code
O=C(O)[C@H](CC1=CC=CC=C1)NC([C@H](CC(O)=O)NC(CCNC(C2=CC=C(C(N)=N)C=C2)=O)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
497.50
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Roux SP, Tschopp TB, Kuhn H, Steiner B, Hadváry P. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog. J Pharmacol Exp Ther. 1993 Jan;264(1):501-8. PubMed PMID: 8423548.
2: Kouns WC, Kirchhofer D, Hadváry P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood. 1992 Nov 15;80(10):2539-47. PubMed PMID: 1384788.
3: Xia Z, Frojmovic MM. Aggregation efficiency of activated normal or fixed platelets in a simple shear field: effect of shear and fibrinogen occupancy. Biophys J. 1994 Jun;66(6):2190-201. PubMed PMID: 8075353; PubMed Central PMCID: PMC1275945.
4: Wang XF, Liu F, Morris SA, Carroll RC. Synergistic outside-in regulation of platelet activation by GPIIb/IIIa ligand-induced conformation and oligomerization. Thromb Res. 2001 Nov 15;104(4):239-47. PubMed PMID: 11728525.
5: Murphy NP, Pratico D, Fitzgerald DJ. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo. J Pharmacol Exp Ther. 1998 Aug;286(2):945-51. PubMed PMID: 9694954.
6: Bernabei A, Gikakis N, Kowalska MA, Niewiarowski S, Edmunds LH Jr. Iloprost and echistatin protect platelets during simulated extracorporeal circulation. Ann Thorac Surg. 1995 Jan;59(1):149-53. PubMed PMID: 7529485.
7: Tanoue K, Katagiri Y, Suzuki H. Molecular mechanisms of fibrin gel clot retraction by platelets and cultured tumor cells. Pol J Pharmacol. 1996 May-Jun;48(3):341-3. PubMed PMID: 9112674.
8: Katagiri Y, Hiroyama T, Akamatsu N, Suzuki H, Yamazaki H, Tanoue K. Involvement of alpha v beta 3 integrin in mediating fibrin gel retraction. J Biol Chem. 1995 Jan 27;270(4):1785-90. PubMed PMID: 7530248.
